Journal of Kidney Cancer and VHL最新文献_第4页

Preserving Renal Function without Compromising Oncological Outcomes: A Comparative Study of Partial and Total Nephrectomies in T3 Stage Renal Cell Carcinoma. 保留肾功能而不影响肿瘤结果：T3期肾细胞癌部分和全部肾切除术的比较研究》（A Comparative Study of Partial and Total Nephrectomies in T3 Stage Renal Cell Carcinoma）。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-12-26 eCollection Date: 2023-01-01 DOI: 10.15586/jkcvhl.v10i4.290

Ahmed Alasker, Turki Rashed Alnafisah, Mohammad Alghafees, Areez Shafqat, Belal Nedal Sabbah, Abdullah Alhaider, Abdulrahman Alsayyari, Naif Althonayan, Mohammed AlOtaibi, Salman Bin Ofisan, Mohammed Alghamdi, Nasser Albogami, Abdullah Al-Khayal

{"title":"Preserving Renal Function without Compromising Oncological Outcomes: A Comparative Study of Partial and Total Nephrectomies in T3 Stage Renal Cell Carcinoma.","authors":"Ahmed Alasker, Turki Rashed Alnafisah, Mohammad Alghafees, Areez Shafqat, Belal Nedal Sabbah, Abdullah Alhaider, Abdulrahman Alsayyari, Naif Althonayan, Mohammed AlOtaibi, Salman Bin Ofisan, Mohammed Alghamdi, Nasser Albogami, Abdullah Al-Khayal","doi":"10.15586/jkcvhl.v10i4.290","DOIUrl":"10.15586/jkcvhl.v10i4.290","url":null,"abstract":"The utility of partial nephrectomy (PN) in locally advanced, stage T3 renal cell carcinoma (RCC) is controversial. This retrospective study aimed to review the oncological and functional outcomes of patients with T3a RCC who underwent PN. We included all patients with pT3a stage RCC undergoing either open, laparoscopic, or robotic PN at our center between January 2015 and 2023. A Wilcoxon rank sum test was utilized to compare nephrectomy types (radical nephrectomy [RN] vs PN). Survival analysis was conducted using Kaplan-Meier plots and a log-rank test. P-value < 0.05 indicated statistical significance. There were no significant differences in demographic characteristics between the RN and PN groups, except age (53.0 vs 6.5, respectively; P = 0.012) and body mass index (28.7 vs 34.3, respectively; P = 0.020). Furthermore, there were also no significant differences in the rates of local recurrence (P = 0.597), metastatic progression (P = 0.129), and chemotherapy use (P = 0.367) between nephrectomy types. Patient survival did not differ significantly based on the type of nephrectomy (log-rank P-value = 0.852). Together, our findings indicated that PN and RN yield near-equivalent oncological outcomes in terms of local recurrence, metastasis, and overall survival rates among pT3a RCC patients during a nearly 3-year follow-up period.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 4","pages":"28-32"},"PeriodicalIF":1.6,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10755761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Papillary Renal Cell Carcinoma: Demographics, Survival Analysis, Racial Disparities, and Genomic Landscape. 乳头状肾细胞癌：人口统计学、生存分析、种族差异和基因组图谱。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-12-26 eCollection Date: 2023-01-01 DOI: 10.15586/jkcvhl.v10i4.294

Asad Ullah, Abdul Qahar Khan Yasinzai, Naema Daino, Bisma Tareen, Zulfiqar Haider Jogezai, Haleema Sadia, Nimra Jamil, Girahnaz Baloch, Adil Karim, Kaleemullah Badini, Agha Wali, Abdul Waheed, Marjan Khan, Bina Asif, Kaleemullah Kakar, Saleh Heneidi, Feroze Sidhwa, Nabin R Karki

{"title":"Papillary Renal Cell Carcinoma: Demographics, Survival Analysis, Racial Disparities, and Genomic Landscape.","authors":"Asad Ullah, Abdul Qahar Khan Yasinzai, Naema Daino, Bisma Tareen, Zulfiqar Haider Jogezai, Haleema Sadia, Nimra Jamil, Girahnaz Baloch, Adil Karim, Kaleemullah Badini, Agha Wali, Abdul Waheed, Marjan Khan, Bina Asif, Kaleemullah Kakar, Saleh Heneidi, Feroze Sidhwa, Nabin R Karki","doi":"10.15586/jkcvhl.v10i4.294","DOIUrl":"10.15586/jkcvhl.v10i4.294","url":null,"abstract":"Papillary renal cell carcinoma (PRCC) is the second most common histological subtype of renal cell cancer. This research aims to present a large database study highlighting the demographic, clinical, and pathological factors, racial disparities, prognosis, and survival of PRCC. The clinical and demographic data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database, and molecular data was cured from the Catalogue Of Somatic Mutations in Cancer (COSMIC) database. PRCC had a median age of diagnosis at 64 years, with a higher incidence in men (77%), and Whites (68%). 70.3% of cases were Grades I-IV (13, 53, 31, and 3%, respectively). In patients with known data, 85% were localized to the kidney, and 84% of cases were 7 cm in size. No metastasis occurred in 97% of the known data. The most common treatment offered was surgical resection (9%). The 5-year overall survival was 79%, with patients undergoing surgery having a 90.6% 5-year survival. Multivariable analysis revealed age > 60 years, Black race, poor histologic differentiation, distant metastases, and tumor size > 10 cm as independent risk factors for mortality. The most common mutations identified from the COSMIC database were MET, KMT2D, KMT2C, ARID1A, and SPEN. PRCC affects male individuals in the sixth decade of life. Increased age, Black race, distant metastases, and tumors > 10 cm are associated with a worse prognosis. Surgical resection offers a favorable survival outcome. Next-generation sequencing (NGS) could identify potentially targetable alterations and future personalized therapeutic approaches.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 4","pages":"33-42"},"PeriodicalIF":1.6,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10755762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of the Patients Aged Less than 40 Years Operated for a Renal Mass 因肾脏肿块接受手术的 40 岁以下患者的特征

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-12-21 DOI: 10.15586/jkcvhl.v10i4.287

Abdullah Ilktac, Bayram Doğan, C. Ersoz, G. Çoban, S. Kalkan

{"title":"Characteristics of the Patients Aged Less than 40 Years Operated for a Renal Mass","authors":"Abdullah Ilktac, Bayram Doğan, C. Ersoz, G. Çoban, S. Kalkan","doi":"10.15586/jkcvhl.v10i4.287","DOIUrl":"https://doi.org/10.15586/jkcvhl.v10i4.287","url":null,"abstract":"The incidence of renal cell cancer (RCC) is low in individuals aged less than 40 years; however several studies have shown this increasing trend over the years. Hereditary syndromes are associated with RCC and are more frequently observed in early-onset cases. In this study, we investigated the characteristics of the patients, aged less than 40 years, who were operated for a renal mass with the suspicion of RCC. We analyzed patients aged <40 years who underwent partial or radical nephrectomy between January 2012 and December 2022. A total of 618 patients underwent partial or radical nephrectomy and 60 (9.7%) patients were aged <40 years. A total of 62 renal masses were resected. The median age of the patients was 34 (31.75–38) years. RCC was detected in 50 (80.6%) lesions, while 12 (19.4%) lesions were benign. The most commonly observed benign tumors were oncocytoma and multicystic nephroma. Low-stage RCC (stage 1) was detected in 78% of patients. Recurrence was observed in two patients and both had von Hippel–Landau gene mutation. During follow-up, two patients were found to have lung metastasis, while another patient had bone metastasis. Three patients died during the follow-up period. Disease free survival rate was 89.58% and cancer specific survival rate was 93.88%. The incidences of kidney cancer in young adults are increasing; therefore, early discovery and the diagnosis are important. Further research is required to gain a better understanding.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"90 2","pages":""},"PeriodicalIF":1.6,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138994154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring Renal Malignancies in Saudi Arabia: Insights from a Tertiary Care Center Study. 探索沙特阿拉伯的肾脏恶性肿瘤：来自三级医疗中心研究的启示。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-12-18 eCollection Date: 2023-01-01 DOI: 10.15586/jkcvhl.v10i4.289

Ahmed Alasker, Turki Rashed Alnafisah, Mohammad Alghafees, Belal Nedal Sabbah, Areez Shafqat, Abdullah Alhaider, Abdulrahman Alsayyari, Naif Althonayan, Mohammed AlOtaibi, Fisal Tariq Aldokhel, Salman Bin Ofisan, Saud Abdullah Alawad

{"title":"Exploring Renal Malignancies in Saudi Arabia: Insights from a Tertiary Care Center Study.","authors":"Ahmed Alasker, Turki Rashed Alnafisah, Mohammad Alghafees, Belal Nedal Sabbah, Areez Shafqat, Abdullah Alhaider, Abdulrahman Alsayyari, Naif Althonayan, Mohammed AlOtaibi, Fisal Tariq Aldokhel, Salman Bin Ofisan, Saud Abdullah Alawad","doi":"10.15586/jkcvhl.v10i4.289","DOIUrl":"https://doi.org/10.15586/jkcvhl.v10i4.289","url":null,"abstract":"This retrospective study aims to describe the characteristics of renal cell carcinoma (RCC) in Saudi Arabia, in terms of epidemiology, clinical presentation, tumor subtype, Fuhrman grade, tumor size and stage, and overall survival. A total of 431 adult patients with a histopathological diagnosis of RCC between 2015 and 2023 were included in the analysis. Most patients (72.4%) had clear cell tumors, followed by chromophobe (15.1%) and papillary (12.5%) subtypes. In males, papillary RCC (85.2%) was more common compared to clear cell (59.8%) and chromophobe (67.7%) subtypes. Significant differences were observed in median body mass index (BMI) across tumor subtypes, and papillary tumor patients exhibited the highest incidence of hematuria (33.3%) compared to other subtypes. The Fuhrman grade also varied significantly among RCC types. Survival times were found to be lower for patients with papillary tumors. No significant difference was observed based on patients' nationality. This study can inform clinical decision-making on patient prognosis and management as well as public health efforts aimed at reducing the alarming rise of RCC incidence.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 4","pages":"13-19"},"PeriodicalIF":1.6,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10739328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sarcomatoid Carcinoma Metastasis to the Colon from a Small Renal Mass: Case Report with Review of Literature. 肾小肿块向结肠转移的肉瘤样癌：病例报告并文献复习。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-10-31 eCollection Date: 2023-01-01 DOI: 10.15586/jkcvhl.v10i4.297

Shailesh Patidar, Arun Ramdas Menon, Shirley Sundersingh, Ramakrishnan Ayloor Seshadri, Anand Raja

引用次数: 0

Advancing Treatment Frontiers: Radiofrequency Ablation for Small Renal Mass-Intermediate-Term Results. 推进治疗前沿：小肾脏肿块射频消融中期结果。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-10-04 eCollection Date: 2023-01-01 DOI: 10.15586/jkcvhl.v10i4.303

Rohit Kumar Singh, Manav Gideon, Rohan Rajendran, Georgie Mathew, Kannan Nair

{"title":"Advancing Treatment Frontiers: Radiofrequency Ablation for Small Renal Mass-Intermediate-Term Results.","authors":"Rohit Kumar Singh, Manav Gideon, Rohan Rajendran, Georgie Mathew, Kannan Nair","doi":"10.15586/jkcvhl.v10i4.303","DOIUrl":"10.15586/jkcvhl.v10i4.303","url":null,"abstract":"Our study aims to discern the immediate and intermediate-term oncological outcomes of the patients with small renal mass and who were surgically unfit or were having a bilateral tumor and underwent radiofrequency ablation (RFA) of the mass. We retrospectively and prospectively analyzed the status of the patients who were diagnosed to have small renal masses and were biopsy-proven renal cell carcinoma (RCC) cases, who underwent RFA at our institute from the year 2013 to 2022. Patients were followed-up for 3 years. Data regarding complications were analyzed for all patients who underwent renal RFA along with the 3-year recurrence-free survival (RFS) rate. A total of 28 patients were eligible for the study based on our inclusion and exclusion criteria. Their renal function was recorded. They underwent RFA and were followed-up for a period of 3 years for RFS. Four patients out of the total had immediate complications, out of which two developed a hematoma. Three-year-follow-ups showed six recurrences, overall having 78.6% RFS. Post-procedural renal function was stable as documented by Estimated glomerular filtration rate. Oncological results of RFA in patients with small renal masses who are surgically unfit are associated with a low risk of immediate and intermediate-term deterioration of renal function.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 4","pages":"1-6"},"PeriodicalIF":1.6,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41183840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case Reports of TFE3-Rearranged Renal Cell Carcinoma: FDG-PET Uptake Might Help Diagnosis. TFE3重排肾细胞癌的病例报告：摄取FDG-PET可能有助于诊断。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-09-27 eCollection Date: 2023-01-01 DOI: 10.15586/jkcvhl.v10i3.266

Sho Murakami, Keita Nagawa, Takanori Inui, Aya Yamamoto, Mizuka Suzuki, Fumitaka Koga, Toru Motoi, Yasunobu Takaki

{"title":"Case Reports of TFE3-Rearranged Renal Cell Carcinoma: FDG-PET Uptake Might Help Diagnosis.","authors":"Sho Murakami, Keita Nagawa, Takanori Inui, Aya Yamamoto, Mizuka Suzuki, Fumitaka Koga, Toru Motoi, Yasunobu Takaki","doi":"10.15586/jkcvhl.v10i3.266","DOIUrl":"https://doi.org/10.15586/jkcvhl.v10i3.266","url":null,"abstract":"Translocation and transcription factor E3 (TFE3)-rearranged renal cell carcinoma (RCC) is a rare subtype of RCCs characterised by the fusion of the TFE3 transcription factor genes on chromosome Xp11.2 with one of the multiple genes. TFE3-rearranged RCC occurs mainly in children and adolescents, although middle-aged cases are also observed. As computed tomography (CT)/magnetic resonance imaging (MRI) findings of TFE3-rearranged RCC overlap with those of other RCCs, differential diagnosis is often challenging. In the present case reports, we highlighted the features of the fluorine-18-labelled fluorodeoxyglucose positron emission tomography with CT (FDG PET-CT) in TFE3-rearranged RCCs. Due to the rarity of the disease, FDG PET-CT features of TFE3-rearranged RCC have not yet been reported. In our cases, FDG PET-CT showed high standardised uptake values (SUVmax) of 7.14 and 6.25 for primary tumours. This might imply that TFE3-rearranged RCC has high malignant potential. This is conceivable when the molecular background of the disease is considered in terms of glucose metabolism. Our cases suggest that a high SUVmax of the primary tumour is a clinical characteristic of TFE3-rearranged RCCs.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 3","pages":"61-68"},"PeriodicalIF":1.6,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy. 晚期和转移性非透明细胞肾细胞癌的系统治疗：研究一种臭名昭著的挑战性恶性肿瘤的现代治疗策略。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-09-26 eCollection Date: 2023-01-01 DOI: 10.15586/jkcvhl.v10i3.295

Jake Drobner, Daniella Portal, Karie Runcie, Yuanquan Yang, Eric A Singer

{"title":"Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.","authors":"Jake Drobner, Daniella Portal, Karie Runcie, Yuanquan Yang, Eric A Singer","doi":"10.15586/jkcvhl.v10i3.295","DOIUrl":"10.15586/jkcvhl.v10i3.295","url":null,"abstract":"Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous group of malignancies that represents 25% of renal cell carcinoma (RCC) cases. Treatment for non-clear cell histologies is mostly based on evidence from small phase II clinical trials or extrapolated from successful therapies in clear cell RCC because of the low incidence of non-clear cell pathology. Advances in genomic profiling have improved clinicians' understanding of molecular targets for nccRCC, such as altered mesenchymal epithelial transition (MET) gene status and fumarate hydratase (FH) gene inactivation, but patient outcomes remain poor and optimal management of this disease remains unclear. This review assesses outcomes by histologic subtype from 27 prospective and 13 ongoing clinical trials to identify therapeutic strategies for advanced or metastatic nccRCC. Vascular endothelial growth factor tyrosine kinase inhibitors (TKI), such as sunitinib, and mammalian target of rapamycin (mTOR) inhibitors, such as everolimus, have demonstrated efficacy and remain viable treatment options, with a preference for sunitinib. However, everolimus is preferred in patients with chromophobe RCC because folliculin (FLCN) gene mutations upregulate the mTOR pathway. Novel TKIs, such as cabozantinib, show improved outcomes in patients with papillary RCC because of targeted MET inhibition. Platinum-based chemotherapy continues to be the recommended treatment strategy for collecting duct and medullary RCC. Clinically meaningful antitumor activity has been observed across all non-clear cell histologies for immune checkpoint inhibitors, such as nivolumab, pembrolizumab, and ipilimumab. Ongoing trials are evaluating novel tyrosine kinase inhibitor and immunotherapy combination regimens, with an emphasis on the promising MET-inhibitor cabozantinib and pembrolizumab plus lenvatinib.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 3","pages":"37-60"},"PeriodicalIF":1.6,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41151679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ligustrazine Inhibits the Migration and Invasion of Renal Cell Carcinoma. 川芎嗪抑制肾细胞癌的迁移和侵袭。

IF 1.9

Journal of Kidney Cancer and VHL Pub Date : 2023-01-14 eCollection Date: 2023-01-01 DOI: 10.15586/jkcvhl.v10i1.232

Xufeng Zhang, Junfu Wang, Yanhua Cao, Kalin Li, Chao Sun, Wen Jiang, Qian Xin, Jue Wang, Tonggang Qi, Shuangde Liu, Yun Luan

{"title":"Ligustrazine Inhibits the Migration and Invasion of Renal Cell Carcinoma.","authors":"Xufeng Zhang, Junfu Wang, Yanhua Cao, Kalin Li, Chao Sun, Wen Jiang, Qian Xin, Jue Wang, Tonggang Qi, Shuangde Liu, Yun Luan","doi":"10.15586/jkcvhl.v10i1.232","DOIUrl":"10.15586/jkcvhl.v10i1.232","url":null,"abstract":"Ligustrazine is a Chinese herb (Chuanxiong) approved for use as a medical drug in China. Recent evidence suggests that ligustrazine has promising antitumor properties. Our preliminary results showed that ligustrazine could inhibit the growth of human renal cell carcinoma (RCC) cell lines. However, the complicated molecular mechanism has not been fully revealed. Therefore, the purpose of this study to investigate the mechanism of ligustrazine resistance in human RCC cells. Cell proliferation, migration, invasion, and colony-formation ability of RCC cells A498 were detected by MTT assay, clonal formation rates, and transwell chamber assay in vitro. The expression of epithelial-mesenchymal transition (EMT)-related proteins were analyzed using western blot test. The effect of ligustrazine on the growth of A498 cells in nude mice was investigated in vivo. Our results showed that ligustrazine could significantly inhibit the proliferation, migration, and invasion of A498 both in vivo and vitro. Western blot analysis showed that the expressions of EMT-related, N-cadherin, snail, and slug proteins were significantly decreased in A498 in the ligustrazine treatment group. This study indicated that ligustrazine could significantly inhibit the malignant biological behaviors of RCC cell lines, possibly by inhibiting the EMT process.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 1","pages":"1-8"},"PeriodicalIF":1.9,"publicationDate":"2023-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10590001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary Well-Differentiated Neuroendocrine Tumor of the Kidney. 原发性肾高分化神经内分泌肿瘤。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-01-01 DOI: 10.15586/jkcvhl.v10i2.277

Vishnu Prasad, Charakkulam Vijay Sreelakshmi, K Ravi Chandran, Shashank Agrawal, Ginil Kumar Pooleri, Amrita Sao

{"title":"Primary Well-Differentiated Neuroendocrine Tumor of the Kidney.","authors":"Vishnu Prasad, Charakkulam Vijay Sreelakshmi, K Ravi Chandran, Shashank Agrawal, Ginil Kumar Pooleri, Amrita Sao","doi":"10.15586/jkcvhl.v10i2.277","DOIUrl":"https://doi.org/10.15586/jkcvhl.v10i2.277","url":null,"abstract":"Primary neuroendocrine tumors (NET) of the kidney are rare. They present with varied symptoms, making their diagnosis difficult clinically as well as pathologically. We present to you the case of a renal NET, which presented in a young female patient. A 48-year-old female patient came with an incidentally detected right renal mass during the evaluation of a nonspecific gynecological problem. She underwent contrast-enhanced computed tomography (CT) of the abdomen, which showed a 57*45*34 mm mass with enlarged retrocaval and aortocaval nodes (25*12 mm). Renal cell carcinoma was suspected as per the CT findings, and metastatic workup in the form of FDG PET CT was done in view of the unusually enlarged nodes. She underwent robot-assisted radical nephrectomy along with lymph node dissection. Surgery was uneventful, and she recovered well in the postoperative period. In the final pathology, there was confusion regarding the diagnosis, and further immunohistochemistry (IHC) was recommended by the pathologist. IHC showed synaptophysin positive, chromogranin negative, CD56 focally positive with Ki-67 of 2-3%, which was suggestive of low-grade NET of the kidney. Lymph nodes were negative. She was kept on follow-up and a Ga 68-DOTANOC scan at 3 months showed no evidence of disease. Diagnosis and management of NET of the kidney still remains a debatable and controversial topic in view of its rarity. High index of suspicion needs to be observed in patients presenting with carcinoid syndrome and a renal mass. Nuclear scans like PET scan and DOTANOC scan can accurately stage the disease. Management includes partial or radical nephrectomy depending on the tumor characteristics. Further studies are required to optimize the treatment protocols for these patients.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 2","pages":"8-12"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9491777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0